Keywords: Bristol-Myers Squibb, Roche, Plexxikon, Daiichi Sankyo, Yervoy, Vemurafenib, ASCO, Metastatic melanoma

Unprecedented survival results for B-MS Yervoy and Roche’s vemurafenib in melanoma discussed at ASCO

Article | 07 June 2011

Print This

There was exciting news presented at this year’s American Society of Clinical Oncology meeting for patients with metastatic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in